Net loss of $1,412,491 for the three months ended June 30, 2024. Elevai’s Chief Executive Officer and Chief Financial Officer, Graydon Bensler stated: “We are excited about our performance in the second quarter of 2024, marked by revenue growth and a solid gross margin. The launch of the B2B/B2C Elevai Skincare e-commerce platform and the establishment of our subsidiaries are pivotal steps in our strategy to streamline operations, maintain focus across the Company and ensure alignment within various departments. As we continue to pursue growth opportunities, we remain committed to identifying additional ways to increase shareholder value through further strategic acquisitions and investments in the biotech, cosmetic, health, and wellness spaces.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAB:
- Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
- Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
- Elevai Labs subsidiary appoints Shirihai to Scientific Advisory Board
- ELEVAI Labs Shares Future Direction and Financial Outlook
- Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line